Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

Post-intravesical BCG epididymo-orchitis: Case report and a review of the literature.

Parker SG, Kommu SS.

Int J Surg Case Rep. 2013;4(9):768-70. doi: 10.1016/j.ijscr.2013.05.017. Epub 2013 Jun 14.

2.

Epididymo-orchitis following intravesical bacillus Calmette-Guérin therapy.

Menke JJ, Heins JR.

Ann Pharmacother. 2000 Apr;34(4):479-82. Review.

PMID:
10772435
3.

Tuberculous epididymo-orchitis following intravesical BCG for superficial bladder cancer.

Bulbul MA, Hijaz A, Beaini M, Araj GF, Tawil A.

J Med Liban. 2002 Jan-Apr;50(1-2):67-9.

PMID:
12841318
4.
5.

"BCGitis": A rare case of tuberculous epididymo-orchitis following intravesical Bacillus Calmette-Guérin therapy.

Demers V, Pelsser V.

J Radiol Case Rep. 2012 Nov;6(11):16-21. doi: 10.3941/jrcr.v6i11.1100. Epub 2012 Nov 1.

6.

Late occurrence of bilateral tuberculous-like epididymo-orchitis after intravesical bacille Calmette-Guérin therapy for superficial bladder carcinoma.

Falkensammer C, Gozzi C, Hager M, Maier H, Bartsch G, Höltl L, Rehder P.

Urology. 2005 Jan;65(1):175.

PMID:
15667898
7.

Intravesical gemcitabine therapy for non-muscle invasive bladder cancer (NMIBC): a systematic review.

Shelley MD, Jones G, Cleves A, Wilt TJ, Mason MD, Kynaston HG.

BJU Int. 2012 Feb;109(4):496-505. doi: 10.1111/j.1464-410X.2011.10880.x. Review.

8.

Conservative treatment of high grade superficial bladder tumours.

Trinchieri A, Bonacina P, Butti A, Cappoli S, Esposito N, Invernizzi S, Librizzi A, Locatelli G.

Arch Ital Urol Androl. 2005 Dec;77(4):215-8.

PMID:
16444936
9.
10.

Intravesical bacillus Calmette-Guerin versus mitomycin C for Ta and T1 bladder cancer.

Shelley MD, Court JB, Kynaston H, Wilt TJ, Coles B, Mason M.

Cochrane Database Syst Rev. 2003;(3):CD003231. Review. Update in: Cochrane Database Syst Rev. 2015;11:CD003231.

PMID:
12917955
11.

Granulomatous epididymo-orchitis, a rare complication of intravesical bacillus Calmette-Guérin therapy for urothelial cancer.

Harving SS, Asmussen L, Roosen JU, Hermann G.

Scand J Urol Nephrol. 2009;43(4):331-3. doi: 10.1080/00365590902930808.

PMID:
19396724
12.

Bladder contracture: review for intravesical bacillus Calmette-Guerin complication.

Hameed A, Sezian N, Thwaini A.

Can J Urol. 2007 Dec;14(6):3745-9. Review.

PMID:
18163926
13.
14.

Bacillus Calmete-Guérin plus interferon-alpha2B intravesical therapy maintains an extended treatment plan for superficial bladder cancer with minimal toxicity.

Lam JS, Benson MC, O'Donnell MA, Sawczuk A, Gavazzi A, Wechsler MH, Sawczuk IS.

Urol Oncol. 2003 Sep-Oct;21(5):354-60.

PMID:
14670544
15.

Diagnosis and management of superficial bladder cancer.

Amling CL.

Curr Probl Cancer. 2001 Jul-Aug;25(4):219-78. Review.

PMID:
11514784
16.

[Granulomatous hepatitis revealing a Mycobacterium bovis widespread infection following intravesical BCG therapy].

Raffray L, Rivière P, Bonnet H, Duffau P, Longy-Boursier M.

Rev Med Interne. 2015 Sep;36(9):626-30. doi: 10.1016/j.revmed.2014.10.361. Epub 2014 Nov 18. French.

PMID:
25467298
17.
18.

Abdominal aortic aneurysmal and endovascular device infection with iliopsoas abscess caused by Mycobacterium bovis as a complication of intravesical bacillus Calmette-Guérin therapy.

Mizoguchi H, Iida O, Dohi T, Tomoda K, Kimura H, Inoue K, Iwata T, Tei K, Miura T.

Ann Vasc Surg. 2013 Nov;27(8):1186.e1-5. doi: 10.1016/j.avsg.2012.12.004. Epub 2013 Aug 21.

PMID:
23972639
19.

A case of Pott's disease with epidural abscess and probable cerebral tuberculoma following Bacillus Calmette-Guérin therapy for superficial bladder cancer.

Josephson CB, Al-Azri S, Smyth DJ, Haase D, Johnston BL.

Can J Infect Dis Med Microbiol. 2010 Spring;21(1):e75-8.

Supplemental Content

Support Center